Shareholder rights law firm launches investigation into Personalis acquisition
Several shareholder rights law firms recently announced that they have filed lawsuits against cancer testing companies. Personalis The transaction to be acquired by Tempus AI has been investigated, focusing on whether the transaction price is fair and whether the board of directors has fulfilled its fiduciary obligations. Under the agreement announced on July 20, Tempus AI will acquire all outstanding shares of Personalis it does not already own for $16.25 per share. After deducting Tempus' existing holdings, the transaction has an enterprise value of approximately $1.5 billion. The purchase price per share represents a 6% premium to the closing price on the last trading day before the announcement and a 28% premium to the unaffected volume-weighted average price on the 30th. Law firms launching the investigation include Brodsky & Smith LLC, Julie & Holleman LLP and Halper Sadeh LLC. The core of the investigation involves two aspects: first, whether the transaction consideration fully reflects the long-term value of Personalis, especially in the context of the continued growth in demand for trace residual disease testing; second, during the sales process, Tempus has established a business partnership with Personalis since 2023 and holds its shares. Whether the possible conflict of interest affects fairness. Personalis is a leader in trace residual disease testing and its NeXT Personal testing technology is known for its ultra-sensitivity. The companies expect the transaction to close by the end of 2026 or early 2027, subject to approval by Personalis shareholders and regulators.